Askgene Pharma, Inc.
Clinical trials sponsored by Askgene Pharma, Inc., explained in plain language.
-
New combo therapy shows promise for tough stomach cancers
Disease control OngoingThis study tests a new drug called ASKB589 combined with standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps control the cancer. The…
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 26, 2026 11:07 UTC
-
New eye injection shows promise for Diabetes-Related vision loss
Disease control OngoingThis early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes blurry vision in people with diabetes. The main goal is to check the drug's safety and how the body processes it. Ab…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for stomach cancer: triple therapy targets tough tumors
Disease control OngoingThis study tests a new drug called ASKB589 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). The goal is to see if the combination helps keep the cancer from growing longer …
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New eye drug ASKG712 enters human testing for blinding disease
Disease control OngoingThis early-stage study tests a new medicine called ASKG712, given as an eye injection, for people with wet age-related macular degeneration (a common cause of vision loss). The main goal is to check safety and how the body handles the drug. About 56 adults aged 50 to 80 with acti…
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC